Advertisement
Advertisement

SCYX

SCYX logo

SCYNEXIS, Inc.

5.24
USD
Sponsored
+0.04
+0.77%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

5.34

+0.10
+2.00%

SCYX Earnings Reports

Positive Surprise Ratio

SCYX beat 30 of 42 last estimates.

71%

Next Report

Date of Next Report
Aug 17, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/
-$0.51
Implied change from Q1 26 (Revenue/ EPS)
--
/
-84.82%
Implied change from Q2 25 (Revenue/ EPS)
-100.00%
/
-54.46%

SCYNEXIS, Inc. earnings per share and revenue

On May 11, 2026, SCYX reported earnings of -3.36 USD per share (EPS) for Q1 26, missing the estimate of -1.00 USD, resulting in a -233.86% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.35% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.51 USD, with revenue projected to reach -- USD, implying an decrease of -84.82% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
logo
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
logo
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
logo
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
logo
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
logo
Profound Medical Corp. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
$0.26
Surprise
+199.01%
logo
OmniAb, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.12
Actual
-$0.05
Surprise
+59.15%
logo
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.48
Surprise
-24.93%
logo
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
logo
Relay Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.41
Surprise
-2.78%
FAQ
For Q1 2026, SCYNEXIS, Inc. reported EPS of -$3.36, missing estimates by -233.86%, and revenue of $0.00, 0% as expectations.
The stock price moved down -5.35%, changed from $0.82 before the earnings release to $0.78 the day after.
The next earning report is scheduled for Aug 17, 2026.
Based on 3 analysts, SCYNEXIS, Inc. is expected to report EPS of -$0.51 and revenue of -- for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement